Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malidi Ahamadi

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Pharmacokinetics and Pharmacodynamics|April 26, 2019
Operating characteristics of stepwise covariate selection in pharmacometric modelingMalidi Ahamadi, Anna Largajolli, Paul M Diderichsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 1, 2019
Population pharmacokinetics of orally administrated bromopride: Focus on the absorption processLarissa Lachi-Silva, Aline B Barth, Gustavo Mendes Lima Santos, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Clinical Pharmacology and Therapeutics|March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting ProgramGerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 3, 2017
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseHongshan Li, Jingyu Yu, Chao Liu, et al.
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Pharmacokinetics and Pharmacodynamics|April 26, 2019
Operating characteristics of stepwise covariate selection in pharmacometric modelingMalidi Ahamadi, Anna Largajolli, Paul M Diderichsen, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|November 1, 2019
Population pharmacokinetics of orally administrated bromopride: Focus on the absorption processLarissa Lachi-Silva, Aline B Barth, Gustavo Mendes Lima Santos, et al.
Journal of Pharmacokinetics and Pharmacodynamics|February 4, 2016
Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working GroupPeter L Bonate, Malidi Ahamadi, Nageshwar Budha, et al.
Clinical Pharmacology and Therapeutics|January 20, 2020
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open DataDaniela J Conrado, Sridhar Duvvuri, Hugo Geerts, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Clinical Pharmacology and Therapeutics|March 23, 2024
Considerations for Industry-Preparing for the FDA Model-Informed Drug Development (MIDD) Paired Meeting ProgramGerald R Galluppi, Malidi Ahamadi, Souvik Bhattacharya, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 3, 2024
Covariate modeling in pharmacometrics: General points for considerationKinjal Sanghavi, Jakob Ribbing, James A Rogers, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 3, 2017
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall responseHongshan Li, Jingyu Yu, Chao Liu, et al.
Clinical Pharmacology and Therapeutics|September 24, 2019
Development of a Disease Progression Model for Leucine-Rich Repeat Kinase 2 in Parkinson's Disease to Inform Clinical Trial DesignsMalidi Ahamadi, Daniela J Conrado, Sreeraj Macha, et al.
Clinical Pharmacology and Therapeutics|August 3, 2023
Model-Informed Drug Development: Steps Toward Harmonized GuidanceScott Marshall, Malidi Ahamadi, Jenny Chien, et al.
Pageof 3